Company

Alion develops therapeutics to treat Central Nervous System disorders and cancers.

At this time, Alion is developing a pipeline of small molecule therapeutics for the treatment of Alzheimer's disease and glioma.

Our focus is ion channels and integral membrane proteins that have been shown to be viable therapeutic targets.

Alion’s proprietary techniques can find small molecules that modulate specific ligand and voltage-gated ion channels, including the AMPA, NMDA, nAch receptors, calcium and potassium ion channels.

Activity or inactivity of ion channels in humans is associated with various diseases. By controlling the functions of specific ion channels, new therapies may be developed. A multi-billion dollar market exists for human ion receptor therapeutics. Twenty-eight ion receptor drugs –that address 5 disctinct targets- generate $12 billion in worldwide sales (Bioportfolio, 2004)

In addition to the development of a therapeutic pipeline, Alion offers early stage pharmaceutical drug development services. These include, identification of lead compounds by computational chemistry and biophysical sceening techniques.

Overview

Alion has extensive computational chemistry experience and facilities. By utilizing computer aided drug design (CADD), we are able to develop models to search our 1.5 million, multi-conformational molecular database for compounds to test in appropriate assays.

Our techniques rapidly exclude the majority of molecules from any database, such that only about 400–700 molecules are selected for screening against a given therapeutic target.

Following the molecular modeling processes and providing a recombinant protein is available for a given therapeutic target, Alion designs and conducts biophysical assays to quickly identify molecules with high affinity for the target.

From our experience, typically 3-5% of the molecules selected by our models, show specific binding to a target molecule and have biological activity.